© 2025 CSRXP- All Rights Reserved

BIG PHARMA EARNINGS WATCH: GILEAD
Feb 13, 2025
Brand Name Drug Company Known for Egregious Product-Hopping Strategy Beats Wall Street Expectations
This week, pharmaceutical giant Gilead reported fourth quarter earnings that beat Wall Street analysts’ expectations after continuing to hike prices on the blockbuster prescription drugs they market.
Gilead also has a track record of blocking competition for drugs in its HIV portfolio through anti-competitive tactics, including an egregious product-hopping strategy that prevented patients from accessing a treatment that would have supported better health outcomes, as noted in a 2023 article by The New York Times.
Get the full report on Gilead’s earnings here:
Gilead
- Gilead reported earnings that blew past Wall Street’s fourth quarter expectations.
- The Big Pharma giant saw total revenue of $7.6 billion, a six percent year-over-year increase, thanks to higher HIV, oncology and liver disease sales.
- HIV therapy Biktarvy reported $3.8 billion in sales, a 21 percent year-over-year increase.
- The company has issued upbeat guidance for 2025.
The strong earnings report from this Big Pharma company follows a pattern of price hikes on
blockbuster products across the company’s portfolios.
Gilead
- Gilead has hiked prices on 11 prescription drugs so far in 2025 at an average rate of 5.9 percent.
- Gilead increased prices on at least 12 prescription drugs in 2024, including HIV drug Biktarvy by 4.9 percent.
- Gilead raised prices on at least 12 prescription drugs in 2023, including best-selling HIV drug Biktarvy by 5.9 percent.
- The brand-name drug maker hiked prices on 11 medications in 2022.
Read more about Gilead’s strategy of patent abuse that delayed access to safer and more effective treatments HERE.
Read more on Q4 earnings from Johnson & Johnson HERE.
Read more on Q4 earnings from AbbVie, Novartis and Roche HERE.
Read more on Q4 earnings from Amgen, GSK and Novo Nordisk HERE.
Read more on Q4 earnings from Merck and Pfizer HERE.
Learn more about solutions to lower prescription drug prices and hold Big Pharma accountable HERE.
###